Musculoskeletal Tumor Registry (MsTR)
The Musculoskeletal Tumor Registry (MsTR) is a national data initiative developed by the American Academy of Orthopaedic Surgeons (AAOS) in collaboration with the Musculoskeletal Tumor Society (MSTS). Originally launched as a feasibility pilot in 2018, the program transitioned to a full registry in 2019 and became the third subspecialty registry in the AAOS family.
MsTR enables orthopaedic oncology practices to collect structured, scalable data on bone and soft tissue tumor procedures across anatomical sites. By aggregating data from participating institutions, the registry helps address clinical questions that are otherwise difficult to study due to the rarity of these diseases.
What’s New
Master Data Dictionary (MDD)
Launched in May 2025, the MDD consolidates registry specifications into a unified schema to streamline data submission, improve accuracy, and reduce file management.
Participation Pathways
MsTR offers two flexible options to accommodate site needs:
- Standard Submission: Requires EHR-abstracted data with provider-entered elements to ensure clinical depth and consistency.
- Alternative Entry Pathway (AEP): A simplified REDCap-based form designed to reduce barriers to initial data collection for both sarcoma and metastatic bone disease cases.
Expanded Scope
The registry now includes a Metastatic Bone Disease module, broadening its relevance and utility for orthopaedic oncology practices.
Platform Modernization
A redesigned data submission platform is planned for launch in Winter 2025, offering improved ingestion and analytics capabilities.
Whether you're an MSTS member or a practicing orthopaedic oncologist, MsTR provides a flexible and clinically meaningful way to contribute to national data efforts.
To learn more or begin enrollment, contact [email protected] or visit the MsTR page on the AAOS website: Musculoskeletal Tumor Registry | AAOS.